此活动已结束，注册已经关闭。在维亚生物科技控股集团中查看更多活动
毛晨
维亚生物董事长&首席执行官2012年8月入选上海市政府“千人计划”专家；2013年3月入选国家“千人计划”专家
康奈尔大学结构生物学博士；杜克大学医学生物学博士后
曾任美国派克-休斯研究所结构生物学部主任
谢屹璟
华兴资本董事总经理谢屹璟先生是华兴资本的联合创始人，目前担任华兴资本董事总经理兼医疗行业团队主管，负责管理医疗行业相关的财务顾问业务。自加入华兴资本以来，谢先生历任多个管理层职位，包括金融投资人团队董事总经理。此前，谢先生曾于Credit Suisse工作，出任该公司投资银行部副总裁。
谢屹璟先生拥有悉尼大学经济学学士学位。
余睿
华兴资本董事总经理Rachel is Managing Director in China Renaissance healthcare and life sciences team; Since joining in CR in 2015, She is responsible for industry and client coverage in Life Science sector and has successfully completed near 30 private financing placement transactions, with total financial amount more than $2bn. Prior to joining CR, Rachel heldd equity analyst position at Deutsche Bank at New York focused on US healthcare equity research; Before that, Rachel worked at Genentech R&D for five years as research associate. Rachel hold an MBA degree from University of Chicago Booth School of Business, and MS in Molecular Pharmacology from University of Missouri - Columbia.
Jonathan Zhu
Managing Director, Bain Capital Private EquityMr. Zhu received a JD from Cornell Law School, an MA from Nanjing University, and a BA from Zhengzhou University in China.
Mr. Zhu joined Bain Capital Private Equity in 2006. He has led many of our investments in China and is currently focused on the Financial and Business Services and Healthcare verticals. Mr. Zhu is Co-head of Asia Private Equity.
Prior to joining Bain Capital Private Equity, was an investment banker at Morgan Stanley and CEO of its China business sector.
陈鹏辉
博远资本创始人陈鹏辉（Kevin Chen），博远资本创始合伙人，专注于医疗大健康领域，在跨国医疗企业和医药投资领域有20逾年的工作经历，具有深厚的海内外行业人脉，又兼有国际化背景。主导及参与投资了华大基因、贝达药业、美中宜和、合全药业、鱼跃医疗、启明瓣膜、挂号网、再鼎医药等多个知名案例。此前是红杉资本中国基金合伙人，负责医疗健康行业投资，并且是美敦力红杉医疗器械创新基金的创始成员和投委会成员。曾是光大控股医疗健康基金创始人和负责人。在此之前任尚华医药总裁、首席运营官及首席财务官。陈鹏辉先生拥有南京大学化学学士学位、杜兰大学药物化学硕士及美国西北大学凯洛格商学院（Kellogg)工商管理硕士学位。
陈怡丹
高特佳执行合伙人美国加州大学圣地亚哥分校医学院药理系博士。曾担任哈佛医学院资深科学家，安捷伦亚太市场首席科学家，技术总监及资深顾问，北京虹博基因战略发展总监，全球医疗高科技风投共同创始人等。作为核心高管或资深顾问促使数家海外及国内企业的并购，上市，融资及权益转让。在医疗健康行业有深厚的专业背景和资源，尤其擅长创投及中美企业商务战略拓展。她还从2014年至今担任全球华人创业协会董事会董事， 2017年1月起担任美国波士顿著名的全球高新技术创业大赛MassChallenge评委。
朱忠远
通和毓承资本合伙人朱忠远博士，通和毓承资本合伙人。朱忠远博士在医疗健康领域拥有超过十五年行业经验。在加入通和毓承之前，朱忠远博士曾任职毓承资本，景林投资，美国应用生物系统等公司。其主要投资案例包括：基石药业、凤凰医疗、华大基因、甘李药业等二十余家公司。朱先生拥有美国麻省大学医学院博士学位和加州大学伯克利分校商学院MBA。
张丹
方恩医药执行董事长张丹于1981-1984年在北京大学生物系医预科就读，并在1984-1989年在北京协和医科大学学习临床医学并获医学博士学位，然后先后在哈佛大学公共卫生学院，宾州大学沃顿商学院等院校进修医院管理，经济学及金融学等，获公卫硕士、医院管理硕士及在读金融学博士。
张丹先后在中国科技部，卫计委，北京市政府，中国医学科学院/协和医科大学、清华大学，北京大学、复旦大学医学院（前上海医科大学），南开大学药学院、华南理工大学及哈尔滨医科大学等做顾问，教授和特邀授课专家。他亲自参与了两个新药在美国的报批（NDA）， 5个全球新药在中国的上市申请，十个在美国上临床证书（IND）的报批。
沈旺
维眸生物科技(上海)有限公司创始人全国“千人计划”专家
在雅培、安进等世界著名制药公司拥有20余年的药物研发经验
启动并领导FDA批准药物Venetoclax的药化发现，主导研发另一FDA批准的干眼症治疗药物Lifitegrast （SAR1118）
发表40多篇核心期刊学术论文并拥有44项个人专利
邹益民
VersaPeutics, Inc.创始人曾任芝加哥大学神经生物学、药理学和生理学助理教授
主要从事轴突导向和神经回路的分子和细胞机制研究工作
发表40多篇核心期刊学术论文
加州大学旧金山分校及圣地亚哥分校神经发育学博士后
Qun(Max) Dang
CEO, InnovStone CSPCMax received his Ph.D. in organic chemistry from Purdue University in 1992.
Max has extensive experiences in business development globally and more than 25-years of experiences as a manager of drug discovery programs spanning from early to late stages; led programs that advanced multiple compounds into human clinic trials ;experiences in therapeutic areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver fibrosis, anemia, viral and bacterial infections; extensive knowledge of SBDD, Medicinal Chemistry, Drug Delivery, Prodrugs, Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside Chemistry; more than 5 years of managing drug discovery programs executed at various CROs. He led to 91 publications and 60 patents.
陈晨
ABM Therapeutics, Inc.创始人德州农工大学博士后研究员
曾在Sundia MediTech担任首席执行官
发表超过110篇研究论文并参与24个专利申请
颜顺启
Arthrosi Therapeutics, Inc.首席运营官 & 创始人罗格斯大学博士
曾在Schrodinger, Arquele等世界著名制药公司就职
主要参与7种临床药物的研发，其中包括2种首创新药
拥有200项专利
Harry Zhou
Founder, Proviva Therapeutics, Inc.Ph.D., New York University，Postdoc., Univ. of Pennsylvania
Over 22 years of experience in R&D of biotherapeutics in metabolic, autoimmune/inflammatory diseases and cancer at Schering AG, Immunex, Amgen, GSK, Fabion Pharmaceuticals, and EMD Serono.
Founder of Fabion Pharmaceutical (USA, 2011)
Founder of EB1 Biotech (Israel, 2018)
叶志雄
维亚生物首席科学官上海“千人计划”专家
明尼苏达大学博士
曾任美国默克公司高级研究员
拥有15年药物发现和临床经验
发表20多篇学术论文并拥有30余项个人专利
许大强
维亚生物首席商务官美国加州大学洛杉矶分校博士
斯克里普斯研究所博士后
宾夕法尼亚大学沃顿商学院MBA
超过25年的药物开发和商业运行的领导经验
曾于普渡制药、山德士、诺华等公司任职
Yiwei Zong
Founder, Anji Pharmaceuticals lncDr. Zong is co-founder and chief operating officer of Anji Pharma. He is an experienced investor and entrepreneur in biotech. He received his Ph.D. in Biomedicine from University of Pennsylvania and is a Chartered Financial Analyst.
Jerry Shen
Chief Executive Officer, AceLink Therapeutics, Inc.Yuqiao (Jerry) Shen, Ph.D.
Chief Executive Officer; Co-founder
Dr. Shen brings more than 20 years of pharmaceutical experience with a focus on drug development for cancer, genetic diseases and rare diseases. Before founding AceLink in 2019, he was Executive Director at BioMarin Pharmaceutical, responsible for small molecule drug discovery and development. He joined BioMarin in 2010 when the company acquired LEAD Therapeutics, a small drug discovery company where he served as VP of Drug Discovery Biology. Prior to LEAD Therapeutics, he served as VP of R&D at Applied Biomics, a protein biomarker research and service company that he co-founded. Prior to that, he worked at Onyx Pharmaceuticals, where he served at positions with increasing responsibilities and helped development of oncolytic viruses and gene delivery viral vectors.
Dr. Shen holds B.S. in Physiology from Fudan University, PhD in Molecular Biology from State University of New York at Buffalo, and received post-doctoral training in Dr. Thomas Shenk’s lab at Princeton University. He has co-authored more than 35 peer-reviewed papers and is a co-inventor in more than 30 issued and pending patents. In 2018, Talazoparib, a cancer drug for which he spent many years of his career both at LEAD and at BioMarin, received marketing approval from FDA.
Hua Lin
Co-Founder, ForkheadbioCo-Founder, Chief Scientific Officer
Completed her Ph.D. at the University of Michigan and was a Postdoc and Assciate Research Scientist at Columbia University before she went on to work as a Senior Resarch Biologist at Merk then as a Team Leader/Principal Resarch Scientist at Eli Lilly.
Kamal Azzaoui
Founder, Saverna Therapeutics AGDr. Kamal Azzaoui received his PhD from the University of Orléans (France) followed by 2 postdocs at McGill University (Montréal) and Georgetown University (Washington DC). Dr. Azzaoui worked for 2 years for a flavor and fragrance mid-size company as a senior computational chemist (Givaudan, Zurich, CH), 2 years as a computational chemist for a biotech startup (Hamit-Darwin-Freesh, Ivins, UT, USA), and 15 years at Novartis as a laboratory head in charge of data analysis, data modeling and drug design using machine learning, cheminformatics and molecular modeling tools. He left Novartis in 2017 to co-found Saverna Therapeutics, and is graduating in November 2019 from the master for advanced science (MAS) program of the Swiss Institute for Translational and Entrepreneurial Medicine (sitem-insel) at the University of Bern. He has contributed to many drug discovery projects in term of data analysis, machine learning, medicinal chemistry and cheminformatics support. He has worked closely with Novartis scientists to develop software such as HTS explorer, a data analysis tool for chemists. He also pioneered in developing machine learning models for the prediction of adverse effects and safety of novel drugs. He was a partner in the European Innovative Medicine Initiative (IMI OpenPhact) consortium. That allows him to interact with highly skilled international scientists and developers from pharmaceutical industry and academia. He has contributed to numerous drug discovery projects by proposing molecules that became lead compounds (one of the proposed molecule series from fragments screening entered the first patient in 2017). Furthermore, based on historical data he identified biological targets and pathways involved in bioactivity during phenotypic screens. Dr. Azzaoui is consulting for Elsevier, Openphact and Axxelis. He received the Novartis Select price in 2007 for hit prioritization from high throughput screening and the Excellence Award price for hit-to-lead Novartis course in 2008.
Richard Austin
CEO, Reglagene Holding, Inc.Richard leads Reglagene’s business operations and fund-raising. Before founding Reglagene, he built a 23- year career in pharmaceutical R&D at GSK and Sanofi in which he served as a medicinal chemist, drug discovery project leader, analytical chemistry services manager, and research operations manager. Recognizing an affinity for the business side of the pharmaceutical industry, in 2010 Richard earned an MBA in Pharmaceutical Management from Drexel University in Philadelphia Pennsylvania. He soon transitioned into a managerial role at Sanofi’s Tucson, Arizona Research Center with responsibilities for operational and capital spending, procurement, equipment maintenance, and other business areas. Richard is a member of Tucson’s Desert Angels, one of the most active angel investment groups in the United States. While serving as a Commercialization Partner for the University of Arizona, Richard was introduced to quadruplex gene expression control. Seeing the potential in the technology, he co-founded Reglagene in November 2016. Richard earned a PhD in Organic Chemistry from the University of Texas in 1991 and completed post-doctoral studies in bioorganic chemistry at the University of California Berkeley in 1993.
Daniele Biasci
Vice President, Totient Inc.Daniele is a research scientist in cancer immunology and leads the human antibodies program at Totient Inc. His research interests focus on genes that drive intratumoral immune response.
During his scientific career, Daniele developed the first and only test to predict clinical outcome in Crohn's disease, currently commercialised by a spinoff of the University of Cambridge (Biasci et al. Gut 2019). He was also the first to show that genetic variants conferring susceptibility to Crohn's disease are completely different from the ones determining disease course, a major determinant of patient well being (Lee, Biasci et al. Nature Genetics, 2017). Daniele completed his PhD in the Faculty of Medicine, University of Cambridge (UK) and was a Research Associate in Cancer Research UK Cambridge Institute. He was awarded a prestigious Schlumberger Research Fellowship in Darwin College, Cambridge (2015-2018).
Guochun Li
Partner, YuanBio Venture CapitalGuochun Li Ph.D. is partner of the YuanBio Venture Capital located in Suzhou, China. He has over 20 years of experience in biologics discovery and investment, with strong experience in leading biologics projects from concept to clinical development. Previously Dr. Li was Chief Scientific Officer of the Gloria Pharmaceuticals company. He served as Research Investigator at the Genomics Institute of the Novartis Research Foundation in US. Dr. Li was graduated from the University of Missouri-Columbia and received postdoctoral training at the University of California, San Diego.
崔志平
复星集团总裁助理2001年至2005年历任上海市医药股份有限公司国际事业部副总监、总经理助理兼国际事业部总经理、副总经理；
2006年至2014年任上海复星医药（集团）股份有限公司副总裁、国际部总经理, 主管公司海外医药企业并购及海外发展战略规划；
2014年至2017年担任上海复星医药（集团）股份有限公司副总裁，VC投资部总经理，主管VC投资；
现兼任复星未来资本副董事长，Amerigen Pharmaceuticals,Ltd,董事，通德股权投资管理（上海）有限公司董事长；
崔志平先生拥有上海医科大学药学学士学位以及澳大利亚拉筹伯大学工商管理硕士学位。
Shixiong Gan
Co-Founder, WisdomontPreviously as Managing Partner/CEO of Gopher Asset Management，Chief Risk Officer of Wanjia Asset Management，General Manager of Investment Banking in Tiantong Securities，Deputy General Manager of Shandong Jintai Co. Ltd, Research Engineer of China National Heavy Duty Truck Group Co. Ltd
26 years of senior management experience in securities, funds and asset management companies; lead the IPO and M&A of more than 80 companies including Suning, SD Gold, SINOTRUCK etc.; successful investment portfolios including Suntech(STP), Yingli(YGE), Concord Medical(CCM),Viva Biotech(01873) etc.; more than 10 years of experience in auto and medical industry; one of the few early participants in stock reform in China.
Education background: Master of Engineering Administration from Tianjin University; Bachelor of Science in Automobile Engineering from Chongqing University